fda warning letters compounded semaglutide tirzepatide 2024 2025 GLP-1s: Why doctors worry and the is cracking down FDA Targets GLP-1 and Peptide

In fact, the opposite may be true

Some analyses show a reduced risk of pulmonary embolism with GLP-1 use, while one 2025 meta-analysis found a significantly higher DVT risk in patients who had been on these medications for more than 78 weeks

Virtual consultations with licensed healthcare providers to determine eligibility and if appropriate, write a prescription for FDA-approved GLP-1 treatments for weight loss

If you are using semaglutide and notice changes in your motivation or focus, its important to work closely with your healthcare provider to ensure the best possible outcomes

Questions to ask your doctor if youre considering a switch: Should I stop semaglutide before starting tirzepatide, or overlap

Ingredients such as high-dose caffeine, synephrine, and green tea extract carry known risks including raised blood pressure, palpitations, and in the case of green tea extract rare but serious liver injury